Staying on 0.25mg Wegovy: Is It the Right Call for You?

Why the 0.25mg dose exists in the first place

The first pen of Wegovy isn't supposed to produce dramatic weight loss. Its job is settling your system into the medicine, reducing the likelihood of nausea, vomiting, and the other gastrointestinal effects that tend to cluster around the early weeks of GLP-1 treatment. That is the design, and it is deliberate.

The 0.25mg Wegovy dose sits at the base of a five-rung ladder. Most clinical guidance, including the Wegovy prescribing information published on the electronic Medicines Compendium (eMC), describes it as a four-week introductory period before moving to 0.5mg. That said, the SmPC acknowledges that if side effects are significant, the prescriber may consider an extended period before titrating. The licence defines the starting point; your prescriber defines the pace.

It helps to know that the appetite-suppression effect many people are seeking becomes more pronounced at higher doses. Early on, at 0.25mg, some people feel very little shift in hunger. That is not a sign the medicine isn't working, it is simply operating at a level chosen for safety, not effect.

Side effects as the primary reason people stay at 0.25mg longer

The most common reason someone chooses (or is advised) to remain at the starting dose a little longer is that their body is still adjusting. Nausea is the one that comes up most often. So are loose stools, burping, and that full-to-the-brim feeling after only a few bites. These tend to ease over time, but the easing is not instant.

If you are still managing meaningful nausea in week three or four, a conversation with your prescriber about extending your time at 0.25mg before stepping up is entirely reasonable. Pushing through a dose increase while side effects are still pronounced rarely makes things easier, and can make them harder.

For practical context on what the half-life of semaglutide means for how symptoms settle between doses, the page on the half-life of Wegovy 0.25mg is worth reading alongside this one. Some people also find that a small routine change helps: keeping the pen in the fridge door and injecting on a consistent day each week, rather than letting the timing drift, removes one source of variation while the body adjusts.

Side effects that are severe or do not ease over several weeks should be reported to your prescriber rather than waited out. The MHRA's Yellow Card scheme also allows patients to report suspected adverse reactions directly.

When staying at 0.25mg is not the right decision

There is a difference between pausing at the starter dose because you need more adjustment time, and staying there indefinitely because the step up feels daunting. The weight-management benefits that Wegovy is licensed to provide are associated with higher maintenance doses, 2.4mg being the standard, with 7.2mg now also MHRA-approved. The 0.25mg level is unlikely to deliver those outcomes over months.

A question our prescribers hear regularly is whether 0.25mg is effective enough on its own. The honest answer is that the clinical trials establishing Wegovy's efficacy (the STEP 1 trial, for instance, which showed around 15% average weight reduction over 68 weeks) were conducted at 2.4mg maintenance dosing. You can read more about what the evidence says on the page covering whether 0.25mg Wegovy is effective.

Staying at 0.25mg long-term is not the same as staying on Wegovy long-term. If you are wondering about the broader question of whether you have to stay on Wegovy indefinitely, that is a separate and genuinely important discussion, one shaped by your individual circumstances, not a one-size answer.

Making the decision with your prescriber

The framing that tends to help most is this: staying at 0.25mg and stepping up are not opposites. One may be the right call for week five; the other for week nine. The titration schedule is a structure, not a strict timetable.

What matters is that the decision is made with clinical input, not guesswork. Your prescriber can look at your side-effect pattern, any relevant health history, and your treatment goals together. That is a very different conversation from asking a forum whether you should just wait another month.

If you are weighing up the semaglutide pathway more broadly (how Wegovy sits within the wider landscape of licensed options) the semaglutide overview and the Wegovy treatment page cover the fuller picture. And if cost is part of what's shaping your thinking, a look at the how to get Wegovy online page walks through what a legitimate private prescription route looks like in the UK.

If you'd like your current situation reviewed by a clinician, our prescribers are available seven days a week. Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not software.